Foundational guide
Sermorelin for Sale USA: A Tucson Lab Signed This Lot
Buyers filter for domestic stock to remove customs, transit heat and the absence of recourse. Worth knowing that the analysis is domestic too, and worth being precise about what a US regulatory position actually gives a research seller, which is less than most listings imply and more than most critics allow.
Sermorelin for sale USA is a filter query, and the thing being filtered for is risk removal rather than quality. Domestic dispatch takes four failure modes off the table and leaves every analytical question exactly where it was.
There is a second domestic fact on this particular listing that gets less attention than it deserves: the laboratory that signed the certificate is also in the United States, with a street address in Tucson, Arizona. A named laboratory at a real address is a claim that can be checked, which is more than an unattributed test result offers.
Supplier publishing lot-level data
Sermorelin, Ascension Peptides
This lot carries a certificate from one independent laboratory. The code below halves the listed price on the vial.
The published certificate for lot 38-01260229 assays this vial at 11.31 mg against a 10 mg label, and reports purity and quantity only, with no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- MZ Biolabs certificate for lot 38-01260229
- Carriage free above $250
- Same-day dispatch before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified September 6, 2026.
Sermorelin for sale USA: what domestic stock removes, and what it does not
The table separates the two columns that listings habitually merge. Everything on the left is a logistics property. Everything on the right is a property of the material, and nothing in the left column touches it.
| Domestic dispatch removes | Because | It leaves unchanged |
|---|---|---|
| Customs interception | No border crossing to be held at | Whether the certificate covers your lot |
| Unpredictable transit time | Domestic carriers publish service levels | Purity, identity and quantity of the powder |
| Cumulative heat exposure | A shorter route is a shorter uncontrolled interval | Whether endotoxin or sterility were tested |
| Unreachable counterparty | A domestic seller sits inside a jurisdiction where a claim can be pursued | Whether the material does anything at all |
Read the right column as the actual shortlist. A buyer who filters for domestic stock and then stops has optimised the part of the transaction that was already the easiest to fix. The document sequence that closes the other column is in our ordering walkthrough.
The other domestic fact: where the analysis was done
Lot 38-01260229 was worked up at 2102 N Country Club Rd in Tucson, Arizona, by MZ Biolabs. Analysis date 7 February 2026, signature 13 February, analyst Ken Pendarvis. The reported figures are 99.79 percent purity and a quantity of 11.31 mg on a 10 mg label, both by HPLC-UV-MS across four detected peaks.
Two identity checks come off the same page without equipment. Convert the printed three-letter sequence and you get YADAIFTNSYRKVLGQLSARKLLQDIMSR: twenty-nine residues, C-terminal amide, canonical GHRH(1-29) amide. Then compare the vendor’s stated C149H246N44O42S at 3357.9 g/mol against PubChem CID 16132413, which returns both.
What that document does not carry is a bacterial endotoxin result or a sterility screen. For a powder that will be reconstituted, that is the most consequential line on the page, and it is a property of this lot rather than of the vendor or the laboratory: test scope is set batch by batch, and certificates for other products from the same seller have carried wider panels on some lots than others.
A named laboratory at a street address is worth more than it looks, because it is falsifiable in a way that an unattributed result is not. An analysis credited to “an accredited third party” cannot be checked, questioned or contacted. One credited to a specific laboratory, with an analyst’s name and a signature date, can be. That does not verify the result, and it does put the document in a category where verification is at least conceivable, which is the meaningful distinction between the two kinds of certificate circulating in this market.
The US regulatory picture, stated accurately
Most pages get this wrong in one of two directions. One says the compound is a banned or unapproved chemical with nowhere lawful to go. The other implies the historic approval somehow covers the vial being sold. Both are contradicted by the same public records.
What the records show: two EMD Serono applications carried the Geref name. NDA 019863 was the pituitary diagnostic, with submissions from May 1991. NDA 020443 was the therapeutic product, approved 26 September 1997. Both are discontinued. There is no current US label, and DailyMed returns no labelling for the substance. A Federal Register determination on the FDA record states that these products were not taken off sale for reasons of safety or effectiveness. That is a commercial ending, not a regulatory verdict on the molecule.
Then the compounding position. FDA’s Category 2 list sets out the bulk drug substances that may present significant safety risks in compounding, and reading it for what is absent is as informative as reading it for what is present. Present on it: ibutamoren mesylate, under both 503A and 503B; ipamorelin acetate; GHRP-2; GHRP-6; kisspeptin-10. Nominated and then withdrawn: BPC-157, Melanotan II, Selank, Semax, MOTS-c, epitalon. Absent from every one of those categories: the compound this page is about. Section 503A lets a compounder work from a bulk substance that was a component of an approved drug product even with no USP monograph covering it, and this one was. The route that follows is our prescription guide.
What research use only labelling does for a US seller
It describes the seller’s position rather than the product’s status. A research-use label is a statement that the seller makes no human-use claim, offers the material for laboratory work, and is not presenting it as a medicine. That is a real constraint on what the listing may say, and it is why a compliant listing carries analytical data and no indications.
What it does not do is confer anything on the powder. It is not a grade, not a certification, and not a regulatory approval of any kind. It does not mean a regulator has reviewed the manufacturing, and it does not mean the material is equivalent to anything dispensed by a pharmacy. Reading the phrase as a quality signal is the single most common misreading in this market, and it runs in the buyer’s disfavour every time.
The practical consequence is that the label tells you where to look rather than what to conclude. Everything the seller is permitted to tell you about the material is on the certificate, which is why the certificate is the document worth opening and the listing copy is not. The channels that produce a different document entirely are compared in our channel guide.
What the domestic option costs
A $99.99 list, a $72.00 site price, and $36.00 once the code is applied. That divides to $3.60 a labelled milligram, or $3.18 against the 11.31 mg this lot assayed. Tiers of 3, 5 and 10 percent reduce the list price independently of the code, and $250 is the carriage threshold.
The evidence position is identical wherever the vial ships from. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics, the PubMed counts run to 332 mentions against three titles, and pairing the compound with anti-aging returns an empty set. ClinicalTrials.gov registers no studies naming the compound: a search returns dozens of records that turn out on inspection to be growth hormone-releasing hormone, tesamorelin and octreotide trials. Domestic dispatch does not change a single one of those numbers.
Frequently asked questions
- What does buying from a US seller actually remove?
- Four things, all logistical. A customs hold that can end in seizure, an unpredictable transit time, the cumulative heat exposure that comes with a long route, and a counterparty outside any jurisdiction where a refund claim can be pursued. It removes none of the analytical uncertainty. A domestic seller publishing no lot-level certificate is selling unverifiable material with a shorter tracking number.
- Where was the linked product actually tested?
- In Tucson, Arizona. The certificate for lot 38-01260229 is issued by MZ Biolabs at 2102 N Country Club Rd, analysed on 7 February 2026 and signed by analyst Ken Pendarvis on 13 February. It reports purity of 99.79 percent and a measured quantity of 11.31 mg against a 10 mg label, by HPLC-UV-MS with four detected peaks. A named laboratory with a physical address is itself a checkable claim.
- Does research use only labelling make a domestic sale legitimate?
- It defines what the seller is not doing rather than granting anything. Material labelled for laboratory use carries no approved indication, no assessed manufacturing quality and no permission to be described as a treatment, and the label is the seller's statement that it makes no human-use claim. It does not confer a regulatory status on the powder, and it does not make the material equivalent to a dispensed medicine.
- Why does the compounding position matter to a US buyer?
- Because it means a lawful prescription route exists alongside the research market, which is unusual here. Section 503A permits a compounder to use a bulk substance that was a component of an FDA-approved drug product, and sermorelin acetate was a component of Geref. Sermorelin is also excluded from FDA's Category 2 list of bulk substances that may present significant safety risks in compounding, in every section of it. A US buyer therefore has a genuine choice rather than a single channel.
- Does a domestic route protect a lyophilised powder better?
- It shortens the interval that nobody measured. A freeze-dried peptide travels better than a solution, and the variable that matters is total time between leaving controlled storage and reaching it again, which a domestic route compresses and a customs hold extends indefinitely. No certificate describes that interval, so shortening it is the only control a buyer has over it.
Limitations of the evidence
Domestic dispatch is a logistics property and this page treats it as one; it says nothing about the composition of any vial. We have not placed an order, tracked a shipment or measured transit temperatures, and the risks described for international routes are structural rather than observed. The analytical figures come from one certificate covering one lot on one analysis date, and its scope is a property of that batch. The regulatory summary describes what public FDA records show about the substance and about compounding, not the legal position of any individual seller, and it is not legal advice. Prices are the vendor's published figures at the review date. Nothing here describes or recommends human use.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.MZ Biolabs, for Ascension Peptides · Certificate of Analysis, sermorelin, lot 38-01260229, quantitative HPLC-UV-MS, analysed 7 February 2026 · 2026Validated
- 2.U.S. Food and Drug Administration · Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks · 2026Validated
- 3.U.S. Food and Drug Administration · Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act · 2026Validated
- 4.U.S. Food and Drug Administration · Drugs@FDA record, NDA 020443, GEREF (sermorelin acetate) for injection, EMD Serono · 1997Validated
- 5.U.S. Food and Drug Administration · Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 78 FR 14095 · 2013Validated